title: Hepatitis C virus-related arthritis.
abstract: Although asymptomatic joint involvement and arthralgias are frequent in patients with hepatitis C virus chronic infection (HCV), a true arthritis affects only up to 4% of the subjects. HCV-related arthritis (HCVrA) is usually distinguished in two clinical subsets: a more frequent symmetrical polyarthritis (SP), similar to rheumatoid arthritis but much less serious, and an intermittent mono-oligoarthritis (IMO) that involves medium and large sized joints, mainly the ankle. This latter subset is strictly related to the presence of HCV-induced mixed cryoglobulinemia and its cutaneous manifestations, in particular purpura. According to recent reports, anti-CCP antibodies are considered very useful in differentiating the SP subset from rheumatoid arthritis. The treatment of HCVrA is still largely empirical because few studies have analyzed this topic. However, COXIBs, NSAIDs, low doses of corticosteroids, hydroxychloroquine and less frequently methotrexate and penicillamine have been used with partial or complete control of symptoms. On the basis of recent studies, the administration of cyclosporine also seems to be sufficiently safe. The scarcely aggressive nature of HCVrA does not favour the use of anti-TNF agents. Specific anti-viral therapy (interferon-alpha+ribavirin) must be accurately evaluated because interferon-alpha can induce the development or the worsening of several autoimmune HCV-related disorders including arthritis.
authors.affiliation: Rheumatology Department of Lucania, San Carlo Hospital of Potenza, Potenza, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Palazzi
authors.forename: Salvatore
authors.initials: S
authors.lastname: D'Angelo
authors.forename: Ignazio
authors.initials: I
authors.lastname: Olivieri
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000842:Ankle / Q000473:pathology / Q000821:virology*; D000914:Antibodies, Viral / Q000096:biosynthesis; D018771:Arthralgia / Q000209:etiology*; D001170:Arthritis, Infectious / Q000150:complications* / Q000821:virology; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000821:virology; D002908:Chronic Disease; D003449:Cryoglobulinemia / Q000276:immunology / Q000821:virology; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D016898:Interferon-alpha / Q000378:metabolism; D008727:Methotrexate / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D011693:Purpura / Q000276:immunology / Q000821:virology
chemical_list: D000305:Adrenal Cortex Hormones; D000914:Antibodies, Viral; D052246:Cyclooxygenase 2 Inhibitors; D016898:Interferon-alpha; D006886:Hydroxychloroquine; D016572:Cyclosporine; D010396:Penicillamine; D008727:Methotrexate